Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America.
The last earnings update was 76 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Argos Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Argos Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Argos Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Argos Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Argos Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Take a look at our analysis of 77AA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Argos Therapeutics's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Argos Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Argos Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Argos Therapeutics's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Argos Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Argos Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if Argos Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Argos Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Argos Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Argos Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Argos Therapeutics's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Argos Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Argos Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Jeffrey D. Abbey, also known as Jeff, M.B.A., J.D., Esq. has been the Chief Executive Officer and President of Argos Therapeutics, Inc. (formerly MERIX Bioscience,Inc) since February 2010. Mr. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. Mr. Abbey served as a Chief Business Officer of Argos Therapeutics, Inc. from January 2009 to February 2010. Mr. Abbey served as Vice President of Business Development of Argos Therapeutics, Inc. since February 2004 until January 2009. Mr. Abbey joined Argos Therapeutics in September 2002. Before joining Argos, Mr. Abbey served as a Vice President of Business Development and Finance at Internet Appliance Network (IAN), a venture-backed information technology company based in New York City. Prior to joining IAN, he was a Partner of Ehrenreich Eilenberg & Krause, where he served as business counsel for a number of life sciences and other emerging technology companies. Mr. Abbey has been a Director of North Carolina Biosciences Organization (NCBIO) since October 26, 2016. Mr. Abbey has been a Director at Argos Therapeutics, Inc. since February 2010. Mr. Abbey holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.
Jeff's compensation has increased whilst company is loss making.
Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Argos Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
VP & CFO
Chief Scientific Officer and VP of Research & Development
Vice President of Finance
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Argos Therapeutics board of directors is about average.
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.